Dimerix Ltd (ASX:DXB, OTC:SBMJF) CEO Dr Nina Webster speaks with Proactive ahead of the Australian Microcap Investment Conference in Melbourne. Dimerix is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. DXB is currently focused on developing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). You can find out more about the 12th Annual Australian Microcap Investment Conference here: www.microcapconferences.com
Dimerix at the Australian Microcap Investment Conference
